A Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics

Pazianas, Michael; Miller, Paul D.; Blumentals, William A.; Bernal, Myriam; Kothawala, Prajesh

doi:10.1016/j.clinthera.2007.08.008

Cited by 252 publications

(203 citation statements)

References 41 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…21,22 There have been recent reports of osteonecrosis of the jaw occurring in cancer patients treated with intravenous bisphosphonates, although it was reported that the prevalence of osteonecrosis of the jaw in patients receiving oral bisphosphonate for treatment of osteoporosis was low. 23 Consistent with these previously reported studies, minor adverse events were observed in only three patients in the risedronate administration group in the present study.…”

Section: Discussionsupporting

confidence: 93%

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Izumi

Mizokami

Sugimoto

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss. Although we reported previously that risedronate significantly recovers bone mineral density (BMD) for up to 12 months, there have been no reports with longer follow-up periods to date. This study extended our earlier series extending the follow-up period to 24 months. Eligible patients had histologically confirmed PCa without lumbar spine metastasis and underwent ADT. Lumbar spine BMD, urinary deoxypyridinoline (uDPD) and serum bone alkaline phosphatase were measured at 6, 12 and 24 months. Among the total of 96 patients, we analyzed 26 and 18 patients in risedronate administration and control groups, respectively. BMD relative to the young adult mean ratio, uDPD and serum bone alkaline phosphatase of the risedronate administration group recovered significantly after 24 months compared with the control group (Po0.0001, P ¼ 0.0001, and Po0.0001, respectively). Transient blurred vision, malaise and vertigo were observed in 1 patient each among the 46 patients treated with risedronate within 28 days after first administration. Oral administration of risedronate is safe and effective for the recovery of ADT-induced bone loss in PCa patients even at 24 months after commencement of treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Izumi

Mizokami

Sugimoto

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Gastrointestinal side effects are well documented in women, although they are also seen in men but at an unclear ratio regarding disease incidence in each sex [12]. Osteonecrosis of the jaw is an exceptional rare entity without sex specificity [41]. The characteristic subtrochanteric fracture associated with bisphosphonate use over 5 years is newly reported and has been described mainly in women [32,37,52].…”

Section: Medication Response and Adherencementioning

confidence: 99%

Sex and Gender Considerations in Male Patients With Osteoporosis

LaMont

Ton

et al. 2011

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Osteoporosis remains underrecognized and undertreated in both men and women, but men who sustain fragility fractures experience greater morbidity and mortality. While men exhibit advanced comorbidity at the time of hip fracture presentation, there are distinct sex-and gender-specific factors related to the pathophysiology and treatment of osteoporosis that further influence morbidity and mortality. Questions/purposes With a selective review of the literature, we evaluated sex-and gender-based differences contributing to increased morbidity and mortality in men with osteoporosis.

show abstract

“…20 Women are prescribed bisphosphonates more commonly than men and therefore a higher prevalence of BONJ in women would be expected. Until further evidence is presented the authors would not consider females at greater risk than males for BONJ.…”

Section: Gendermentioning

confidence: 99%

Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm

Malden

Beltes²,

Lopes

2009

Br Dent J

View full text Add to dashboard Cite

A Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics

Cited by 252 publications

References 41 publications

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Sex and Gender Considerations in Male Patients With Osteoporosis

Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm

Contact Info

Product

Resources

About